Evaluation of in vitro activity of ceftolozane/tazobactam and comparators against recent clinical bacterial isolates, and genomics of Pseudomonas aeruginosa, Klebsiella pneumoniae and Escherichia coli isolates that demonstrated resistance to ceftolozane/tazobactam: data from Kuwait and Oman

BACKGROUND: The treatment options for infections caused by MDR Gram-negative bacteria have been limited, especially for infections caused by bacteria that produce carbapenemases and/or ESBLs. Ceftolozane/tazobactam is a cephalosporin/β-lactamase inhibitor developed to treat Gram-negative bacteria. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Alfouzan, Wadha, Dhar, Rita, Mohsin, Jalila, Khamis, Feryal, Mokaddas, Eiman, Abdullah, Abrar, Mustafa, Abu Salim, Otero, Aurelio, Wanis, Paulette, Matar, Samar Hussien, Khalil, Sherif, Alekseeva, Irina, Young, Katherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021015/
https://www.ncbi.nlm.nih.gov/pubmed/35465239
http://dx.doi.org/10.1093/jacamr/dlac035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021015/
https://www.ncbi.nlm.nih.gov/pubmed/35465239
http://dx.doi.org/10.1093/jacamr/dlac035

Ejemplares similares